Skip to main content
. 2018 Jun 25;9:1454. doi: 10.3389/fimmu.2018.01454

Table 2.

Summary of published studies of HHV-6 T-cell antigens.

Study Approach Methods CD4 T-cell antigens confirmed CD8 T-cell antigens confirmed
Martin et al. (104) CMV homolog selection and epitope prediction (HLA-A*0201) ELISA, multimer staining, cytotoxicity assay (NA) U11, U54

Nastke et al. (51) Computer-based epitope prediction (DRB1*0101) Cytokine bead assay, intracellular cytokine secretion (ICS), ELISpot, HLA-peptide tetramer staining U11, U14, U38, U48, U54, U47 (NA)

Gerdemann et al. (40) CMV homolog selection ELISpot, ICS, cytotoxicity assay (NA) U11, U14, U54, U71, U90

Iampietro et al. (115) CMV homolog selection ICS, ELISA, cytotoxicity assay (NA) U54

Becerra-Artiles et al. (107) Selection by antigenic gel fractions of HHV-6B proteins followed by computer-based epitope prediction (DRB1*0101) ELISA, ELISpot, mass spectrometry, SDS-PAGE, fluorescence-polarization HLA peptide-binding competition assay U11, U14, U31, U39, U41, U48, U54, U57, U90, U100 (NA)

Halawi et al. (105) CMV homolog selection ICS, ELISpot, ELISA (NA) U11, U90

Martin et al. (109) Computer-based epitope prediction (HLA-B*0801) ELISA, ELISpot, cytotoxicity assay, HLA-peptide multimer staining (NA) U3, U7, U26, U29, U31, U38, U41, U42, U53, U59, U64, U72, U79, U84, U86, B4